Skip to content

Repetitive Transcranial Magnetic Stimulation Use in Acute Stroke

Real vs Sham rTMS Combined With Conventional Therapy in Acute Stroke

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01922986
Enrollment
4
Registered
2013-08-14
Start date
2013-09-30
Completion date
2015-03-31
Last updated
2017-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Keywords

stroke, rehabilitation, hemiplegia, repetitive transcranial magnetic stimulation

Brief summary

When a certain area of the brain is injured, like in stroke, several events occur. One side of the body may become weak. This weakness is called hemiparesis and it may create difficulty in performing tasks like writing, eating, and walking. The weakness results from two sources: 1. death of some brain cells in the affected side (hemisphere) of the brain 2. exaggerated inhibitory signals from the unaffected hemisphere acting on surviving neurons in the affected hemisphere. Investigators cannot change neurons that have died but they may be able to change the exaggerated inhibition that impairs the surviving neurons in the affected hemisphere.The purpose of this study is to try to decrease the exaggerated inhibition coming from the unaffected hemisphere, which suppresses the affected hemisphere, with transcranial magnetic stimulation (TMS). Investigators hypothesize that, from admission to discharge, active rTMS combined with conventional therapy will produce greater functional gains in the paretic hand compared to sham rTMS combined with conventional therapy, as measured by standard tests.

Detailed description

Stroke is the leading cause of long-term disability in the United States and people with stroke deserve our maximum effort to restore in them as much function as possible; yet, mainstream stroke rehabilitation remains mired in traditional treatment approaches that may be suboptimal. However, for the past 5 years we have been endeavoring to advance stroke rehabilitation by including noninvasive brain stimulation. This study will explore whether the safety and functional results from noninvasive brain stimulation in patients with chronic stroke when given by researchers in a laboratory setting can be replicated in acute stroke when given by trained clinicians in the real-world clinical setting. As background, a phenomenon in stroke is that compensatory overuse of the non-stroke hemisphere can inhibit surviving neurons in the stroke hemisphere. In this way, people with stroke are doubly disabled - first, by the stroke itself and, second, by exaggerated interhemispheric inhibition (IHI) arising in the non-stroke hemisphere and acting on surviving neurons in the non-stroke hemisphere. Investigators cannot bring the killed neurons back to life but they can up-regulate the surviving neurons suppressed by IHI. Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive way to do this. rTMS has not yet entered mainstream clinical use for stroke, likely because it has not been explored in the acute rehabilitation setting with application by clinicians. With prior National Institutes of Health funding, Dr. Carey has considerable experience in using rTMS in the laboratory setting for chronic stroke. He will now take rTMS out of his lab and into the real-world setting of Courage Kenny Rehabilitation Institute (CKRI), the primary referral center for acute stroke rehabilitation in our region, where clinicians will be trained in rTMS. Five daily rTMS treatments (active or sham) will be given to the non-stroke primary motor area (M1). After each treatment, patients will receive their conventional rehabilitation training. This approach is innovative because of the rTMS parameters used and because the application will be given by trained clinicians with oversight by the Principal Investigator, as opposed to laboratory researchers. Expected outcomes are improved hand function with no major adverse effects. Data will serve as a springboard to larger clinical trials. Specific Aim #1: Determine the safety of 5 treatments of 6-Hz primed low-frequency rTMS combined with conventional therapy in adults with acute stroke. Adverse effects will be measured through observation for seizures, investigator screening, physician exam, and tests of cognitive function and motor function in the nonparetic hand. Investigators hypothesize there will be a) no seizures, b) no cognitive decline and c) no motor decline. Specific Aim #2: Compare the effectiveness of active vs. sham rTMS on functional outcomes in adults with acute stroke. Adults with acute stroke will be randomized to receive either active rTMS or sham rTMS. Both groups will also receive conventional therapy, consisting of the normal rehabilitation used at this rehabilitation center. Investigators hypothesize that, from admission to discharge, active rTMS will produce greater functional gains in the paretic hand compared to sham rTMS, as measured by standard tests.

Interventions

DEVICEactive rTMS

10 minutes of real high-frequency (6-Hz) rTMS priming (total priming pulses = 600) plus 10 minutes of low-rate (1Hz) rTMS (total low-rate pulses = 600).

DEVICEsham rTMS

20 minutes of sham rTMS stimulation

BEHAVIORALconventional stroke therapy

conventional stroke therapy consisting of exercises and physical training

Sponsors

University of Minnesota
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* stroke onset: within past 30 days but rTMS intervention will commence no sooner than 5 days from stroke onset * stroke location: cortical or subcortical * stroke type: ischemic * age: \>18 years * paretic index finger must show either no or impaired flexion/extension motion at the metacarpophalangeal (MP) joint. * Mini-Mental State Examination greater than or equal to 22 * ability to stand/transfer with no more than moderate assistance

Exclusion criteria

* seizure within past two years * metal in head (dental permitted) * pregnancy * psychiatric disorders * receiving tricyclic antidepressants or neuroleptics * inability to follow three-step command * hemineglect * dependent on ventilator, nasogastric tube, or implanted medical device * co-morbidities impairing upper extremity function * anticipated stay at Courage Kenny Rehabilitation Institute shorter than 7 treatment days

Design outcomes

Primary

MeasureTime frameDescription
Percent Change From Baseline in Jebsen Taylor Hand Function Test ScoresMeasured at pretest (day before treatments begin) and posttest (day following last treatment). Thus, 7 days of participation (1 pretest, 5 treatments, 1 posttest).This test quantifies the time it takes for the subject to do the following standardized functional tasks with the hand: stack three checkers, turn over cards, turn over empty cans, turn over fluid-filled cans, pick up and place small items like a paper clip, etc into a can, and use a spoon to scoop up a bean and drop the bean into a can. The unit of measure is time and changes that are negative signify reduced time at posttest compared to pretest, which would be an improvement. Total score = sum of times for each subtests

Secondary

MeasureTime frameDescription
Change in Finger Tracking TestMeasured at pretest (day before treatments begin) and posttest (day following last treatment). Thus, 7 days of participation (1 pretest, 5 treatments, 1 posttest).This test involves placing a device on the hand that shows the changing angle of the finger joint on a computer screen as the joint is moved. The computer screen also shows a target line, such as a sine wave. At the start of the test, the computer screen cursor moves horizontally across the target and the subject moves the finger joint into extension or flexion to adjust the vertical position of the cursor to that it traces the target line as accurately as possible. The performance is quantified by calculating the root-mean-square error between the target line and the response line. This is converted into an Accuracy Index, which has a maximum value of 100% (perfect score). Negative values can occur and reach a value of -100%, signifying very poor performance. Typical scores for healthy range from 50-80%. Typical values in stroke range from -100 to +40%. Changes that are positive signify increased tracking accuracy at posttest compared to pretest, which would be an improvement.
Change in Motricity IndexMeasured at pretest (day before treatments begin) and posttest (day following last treatment). Thus, 7 days of participation (1 pretest, 5 treatments, 1 posttest).Measures strength in finger pinch, elbow flexion and arm abduction. 0 No pinch movement. 11 Slight movement of finger or thumb. 19 Able to grip the cube, but not hold it against gravity. 22 Able to grip and hold the cube against gravity, but not against a weak pull by examiner. The weighted score based on the ordinal 6 point scale 26 Able to grip and hold the cube against a weak pull, but weaker than the other side. 33 Normal pinch grip. For shoulder and elbow scoring is: 0 No movement. 9 Palpable contraction in muscle, but no movement. 14 Visible movement, but not full range and not against gravity. 19 Full range of movement against gravity but not against resistance. 25 Full movement against resistance, but weaker than the other side. 33 Normal power. Maximum total score is 99, minimum is 0. Changes that are positive signify improved strength at postte

Countries

United States

Participant flow

Participants by arm

ArmCount
Active rTMS With Conventional Therapy
20 minutes of active rTMS followed by conventional stroke therapy active rTMS: 10 minutes of real high-frequency (6-Hz) rTMS priming (total priming pulses = 600) plus 10 minutes of low-rate (1Hz) rTMS (total low-rate pulses = 600). conventional stroke therapy: conventional stroke therapy consisting of exercises and physical training
2
Sham rTMS With Conventional Therapy
20 minutes of sham rTMS stimulation followed by conventional stroke therapy sham rTMS: 20 minutes of sham rTMS stimulation conventional stroke therapy: conventional stroke therapy consisting of exercises and physical training
2
Total4

Baseline characteristics

CharacteristicActive rTMS With Conventional TherapySham rTMS With Conventional TherapyTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
1 Participants1 Participants2 Participants
Age, Categorical
Between 18 and 65 years
1 Participants1 Participants2 Participants
Age, Continuous73.5 years
STANDARD_DEVIATION 19.1
52.5 years
STANDARD_DEVIATION 23.3
63.0 years
STANDARD_DEVIATION 21.2
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
2 Participants2 Participants4 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
2 Participants2 Participants4 Participants
Region of Enrollment
United States
2 participants2 participants4 participants
Sex: Female, Male
Female
1 Participants0 Participants1 Participants
Sex: Female, Male
Male
1 Participants2 Participants3 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 20 / 2
serious
Total, serious adverse events
0 / 20 / 2

Outcome results

Primary

Percent Change From Baseline in Jebsen Taylor Hand Function Test Scores

This test quantifies the time it takes for the subject to do the following standardized functional tasks with the hand: stack three checkers, turn over cards, turn over empty cans, turn over fluid-filled cans, pick up and place small items like a paper clip, etc into a can, and use a spoon to scoop up a bean and drop the bean into a can. The unit of measure is time and changes that are negative signify reduced time at posttest compared to pretest, which would be an improvement. Total score = sum of times for each subtests

Time frame: Measured at pretest (day before treatments begin) and posttest (day following last treatment). Thus, 7 days of participation (1 pretest, 5 treatments, 1 posttest).

ArmMeasureValue (MEAN)Dispersion
Active rTMS With Conventional TherapyPercent Change From Baseline in Jebsen Taylor Hand Function Test Scores-23.0 percentage of change from baselineStandard Deviation 32.5
Sham rTMS With Conventional TherapyPercent Change From Baseline in Jebsen Taylor Hand Function Test Scores0 percentage of change from baselineStandard Deviation 0
Secondary

Change in Finger Tracking Test

This test involves placing a device on the hand that shows the changing angle of the finger joint on a computer screen as the joint is moved. The computer screen also shows a target line, such as a sine wave. At the start of the test, the computer screen cursor moves horizontally across the target and the subject moves the finger joint into extension or flexion to adjust the vertical position of the cursor to that it traces the target line as accurately as possible. The performance is quantified by calculating the root-mean-square error between the target line and the response line. This is converted into an Accuracy Index, which has a maximum value of 100% (perfect score). Negative values can occur and reach a value of -100%, signifying very poor performance. Typical scores for healthy range from 50-80%. Typical values in stroke range from -100 to +40%. Changes that are positive signify increased tracking accuracy at posttest compared to pretest, which would be an improvement.

Time frame: Measured at pretest (day before treatments begin) and posttest (day following last treatment). Thus, 7 days of participation (1 pretest, 5 treatments, 1 posttest).

ArmMeasureValue (MEAN)Dispersion
Active rTMS With Conventional TherapyChange in Finger Tracking Test24.5 units on a scaleStandard Deviation 25.2
Sham rTMS With Conventional TherapyChange in Finger Tracking Test-13.8 units on a scaleStandard Deviation 41.8
Secondary

Change in Motricity Index

Measures strength in finger pinch, elbow flexion and arm abduction. 0 No pinch movement. 11 Slight movement of finger or thumb. 19 Able to grip the cube, but not hold it against gravity. 22 Able to grip and hold the cube against gravity, but not against a weak pull by examiner. The weighted score based on the ordinal 6 point scale 26 Able to grip and hold the cube against a weak pull, but weaker than the other side. 33 Normal pinch grip. For shoulder and elbow scoring is: 0 No movement. 9 Palpable contraction in muscle, but no movement. 14 Visible movement, but not full range and not against gravity. 19 Full range of movement against gravity but not against resistance. 25 Full movement against resistance, but weaker than the other side. 33 Normal power. Maximum total score is 99, minimum is 0. Changes that are positive signify improved strength at postte

Time frame: Measured at pretest (day before treatments begin) and posttest (day following last treatment). Thus, 7 days of participation (1 pretest, 5 treatments, 1 posttest).

ArmMeasureValue (MEAN)Dispersion
Active rTMS With Conventional TherapyChange in Motricity Index4 units on a scaleStandard Deviation 5.7
Sham rTMS With Conventional TherapyChange in Motricity Index11 units on a scaleStandard Deviation 0

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026